16 封面專題 • COVER STORY 澳大新語 • 2024 UMAGAZINE 30 胡元佳教授 Prof Hu Yuanjia pharmaceutical regulatory experts, scholars, and policymakers from Macao, mainland China, Southeast Asia, Portuguese-speaking countries, and beyond, aiming to establish a collaborative and exchange platform among industry, academia, research institutions, and government departments in medical product regulation and innovation. Prof Hu says, ‘CPRS will keep expanding its role to further support the development of pharmaceutical services and the industry in Macao.’ Establishing Quality Standards for Chinese Medicine Internationally recognised quality standards are essential to bringing Chinese medicine to the global market. Therefore, SKL-QRCM is actively developing innovative quality analysis methods and international standards. The unit has established joint laboratories with the United States Pharmacopeia Convention, the European Pharmacopoeia Commission, and China’s National Institutes for Food and Drug Control, respectively. These joint laboratories have completed or are working on including more than 20 Chinese medicine quality standards in the United States Pharmacopeia, European Pharmacopoeia, and Chinese Pharmacopoeia. These standards cover key medicinal ingredients, including Panax notoginseng, ophiopogon root, goji berries, cordyceps militaris, artificial cordyceps powder, galangal, dendrobium, patchouli, and amla. When it comes to the establishment of Chinese medicine quality standards, SKL-QRCM focuses on core quality elements and developing innovative methods and applications. In 2016, SKL-QRCM, ICMS, and Peking Union Medical College conducted a research project focused on using DNA barcoding for species identification of medicinal plants, which was awarded a second prize of the State Scientific and Technological Progress Award. Committed to Making a Social Impact From drug development to product and service launch, and ultimately to promoting the development of the Chinese medicine industry, this journey is long and full of challenges. The process requires close collaboration between government departments, research institutions, and industry. Throughout this process, UM is committed to translating more Chinese medicine research results into practical applications, thus making contributions to the sustainable development of the Chinese medicine industry. 澳大已立項和制定20餘項《美國藥典》、《歐洲藥典》及《中國藥典》標準 UM scholars have completed or are working on including over 20 quality standards in the United States Pharmacopeia, European Pharmacopoeia, and Chinese Pharmacopoeia.
RkJQdWJsaXNoZXIy NzM0NzM2